LifeMine Therapeutics Funding, Investors & Competitors

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

Anew Labs is a platform developer that builds artificial intelligence systems for identifying pharmaceutical compounds, such as predicting molecular shapes and designing antibodies, by combining computational work with laboratory validation targeting inflammatory diseases.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Merck KGaA operates in three main segments: life science, electronics, and healthcare. The life science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Iflytek Co Ltd is a China-based company, principally engaged in the software and information technology (IT) service businesses. The company’s business includes intelligent application systems, software for voice and speech recognition and conversion, computer software design services, and computer programming services. The company's main products include AI language learning products, AI learning machines, AI diagnosis and treatment assistant products, smart medical devices, the iFLYTEK Hearing Smart Conference System, the iFLYTEK Spark App, the iFLYTEK Smart Office Book, the iFLYTEK Translator, and others.

Institut Mérieux is a biomedical research foundation based in Lyon, France, developing diagnostics, vaccines, and therapies against infectious diseases and cancer. Part of the Mérieux family enterprises, it funds projects in antibiotic resistance, emerging pathogens, and immuno-oncology through partnerships with INSERM and international consortia like CEPI.

Color is a health technology platform delivering population genomics, cancer screening, and COVID-19 testing programs for employers, schools, and governments. Headquartered in Burlingame, California, it processes whole-genome sequencing through CLIA-certified labs and partners with health systems like Kaiser Permanente for nationwide deployment.

Megvii, also known by its Face++ brand, is a Beijing-based artificial intelligence company, founded in 2011 by Tsinghua University graduates, that develops computer vision technology for facial recognition, object detection, and related applications. Its systems are used in public security, mobile payments, and consumer devices by clients including Alibaba, Ant Financial, Lenovo, Foxconn, and Xiaomi, and its technology has supported thousands of arrests by China's Ministry of Public Security. The company has pursued a public listing in Hong Kong as it expands internationally.

Astromech is an artificial intelligence company spun out of Colossal Biosciences, founded by Ben Lamm. It uses AI to analyze biological data and forecast evolution and disease risk, applying its platform to biotech research.

Allen Control Systems is an Austin, Texas-based defense technology company that builds autonomous precision weapon systems for counter-drone defense. Its flagship product, Bullfrog, is an AI-powered robotic weapon station that uses computer vision and proprietary control systems to integrate with legacy and modern weapons, including the M240 and M2, for precision targeting against unmanned aerial threats. Founded by former U.S. Navy engineers, the company sells to the U.S. Department of Defense and allied militaries.

Insitro is a drug discovery company integrating machine learning with high-throughput biology to identify novel therapeutic targets. South San Francisco-headquartered and founded in 2018, it generates functional genomic datasets from bioengineered cell models aligned with patient clinical data. Insitro's predictive models accelerate small molecule development for diseases like oncology and fibrosis. The company collaborates with pharmaceutical partners on precision medicine programs using its industrial-scale wet lab facilities.

Inari is a West Lafayette-headquartered biotechnology company developing seed traits through multiplex gene editing and predictive design via its SEEDesign platform. The firm targets corn, soybean, and wheat improvements for yield, drought tolerance, and nitrogen use efficiency. Founded in 2016, Inari operates greenhouses and field trial sites across the US Midwest and Brazil. It collaborates with Corteva and Bayer on commercialization pipelines for hybrid varieties suited to diverse climates.